The Skin longevity protocol is not suitable for every patient. This page clearly identifies which profiles benefit from the protocol and which require more specialized referrals. Transparency is the foundation of clinical ethics.
Last reviewed: 2026-05-26
The Skin longevity protocol is planned in three bands: preventive ages 25–35 (slowing collagen loss, photoprotection, micro-interventions), corrective ages 35–55 (volume restoration, biostimulation, energy-based tightening), maintenance ages 55+ (sustaining existing structure with conservative doses). Cases outside these bands (e.g. under-20 without indication, 65+ with high comorbidity) are evaluated individually.
The goal of Skin longevity is not to halt aging or reverse it by 10 years — it is to preserve skin health, tissue quality and facial proportion in a way that is consistent with age. The ideal candidate arrives with the goal of "looking natural, rested and healthy". Specific requests such as "looking like a particular celebrity" or "looking unrecognizable" are addressed transparently in the initial consultation, and additional counseling may be recommended before any tretman.
The protocol is not a one-time procedure — it is a series of small, measured interventions sustained over years. The ideal candidate can attend at least 2 (typically 3–4) follow-up visits per year and understands the value of long-term monitoring. A "one session and I never want to come back" approach does not align with the core logic of Skin longevity; in that case shorter-term alternative tretman options are discussed with the patient instead.
In-clinic interventions become sustainable only when paired with a daily baseline routine: broad-spectrum SPF 30+ (every day), a nighttime retinoid (within tolerance), a morning vitamin C/E antioxidant serum, and where indicated oral collagen / omega-3 / vitamin D supplementation. The ideal candidate is open to adopting this routine. A patient who declines the routine can reduce the yield of clinical interventions by up to half, and this is discussed openly.
Smoking accelerates dermal collagen and elastin breakdown, impairs microcirculation, increases oxidative stress, and in clinical studies smokers age cutaneously approximately 4× faster than non-smokers. The collagen response to biostimulators and energy-based tretmani used within the Skin longevity protocol is significantly reduced in smokers. The ideal candidate is either a non-smoker or in a cessation process and open to receiving guidance from the clinic on this topic.
The ideal candidate is someone who largely accepts themselves as they are and views an aesthetic intervention not as a "rescuer" but as part of personal care. If the pre-tretman consultation reveals excessively focused perception of a perceived flaw, repeated and unsatisfiable correction requests, or a recent major personal loss, psychological support is recommended prior to any intervention. This is a standard protective step, not a rejection.
Because Skin longevity is a multi-year follow-up relationship, the ideal candidate has regular access to the clinic (Ataşehir, Istanbul) or can make periodic check-up visits from another city or abroad. Single, long-distance applications reduce protocol yield due to broken follow-up planning, and such patients are clearly informed about remote-follow-up limitations and offered alternative plans (annual check + interim local dermatologist).
During pregnancy and lactation, interventions within the Skin longevity protocol — botulinum toxin, fileri, biostimulators, energy-based tretmani, and many topical actives (retinoids, hydroquinone, etc.) — are not performed because clinical safety data is insufficient. This is not an absolute contraindication but a postponement based on lack of evidence. Re-evaluation is performed at least 3 months postpartum and after lactation ends.
In the presence of active herpes simplex (cold sore) reactivation, acute dermatitis, flared eczema, impetigo or similar infections in the tretman area, the intervention is postponed. Otherwise, risks include spread of infection, scarring and unwanted pigmentation. In patients with a history of herpes simplex, a prophylactic antiviral protocol is considered before filer/laser. The plan is rebuilt after complete healing.
In active-phase systemic lupus erythematosus, scleroderma, dermatomyositis and similar connective-tissue diseases, fileri or energy-based injury can provoke unexpected immune responses; risks include granuloma formation, exaggerated reaction to biostimulators, and further deterioration of tissue quality. The active disease period is therefore a relative contraindication. Once stable remission and appropriate drug regimens are confirmed by the rheumatology team, a case-by-case evaluation is performed jointly with the specialist.
In patients on warfarin with INR above 3 or on dual antiplatelet therapy (e.g. aspirin + clopidogrel), injection-based procedures carry significant risks of bruising, hematoma and rarely vascular complications. In such patients the procedure is evaluated in coordination with the supervising cardiology/internal-medicine physician; if tretman is not essential it is postponed, and if essential only lower-risk interventions (e.g. topical protocols, carefully chosen energy-based tretmani) are discussed.
In patients who have developed keloid scars from minor trauma in the past (e.g. piercings, surgical incisions), interventions that create micro-injury — microneedling, fractional laser, deep filer injection, PRP — can increase the risk of uncontrolled scar growth. Such patients are evaluated case-by-case after a pre-clinical test-spot application and detailed risk counseling; in most cases these procedures are not performed and alternatives with lower dermal trauma are planned instead.
During the consultation, signs such as excessive focus on an objectively minor or non-existent flaw, constant mirror-checking that significantly affects daily life, or persistent dissatisfaction despite repeated previous corrective interventions to the same area, suggest BDD. In this setting an aesthetic intervention does not resolve the symptoms and may worsen them. The patient's priority is a psychiatry referral — this is not a refusal of tretman but a redirection to the right timing and the right specialist.
For patients arriving with very specific numerical goals such as "looking 10 years younger", "completely smooth skin" or "looking like the person in this photo", the Skin longevity protocol cannot promise those outcomes. With these patients the pre-tretman consultation is extended, and a realistic expectation range (e.g. "a natural, rested, healthy appearance plus measurable improvement in skin quality") is discussed transparently. If the patient does not move into this revised expectation frame, tretman is not initiated.
In the presence of active atopic dermatitis or a flared eczema on the face, cosmetic interventions are not the priority — the skin barrier function must first be stabilized under dermatology follow-up with topical calcineurin inhibitors, topical corticosteroids or, where needed, systemic tretman. Once the skin has settled, the Skin longevity protocol is re-evaluated; communication with the patient is kept open throughout the process.
Grade III–IV inflammatory acne (widespread nodulocystic lesions, scar development) should not be managed via Skin longevity but under dermatology follow-up with systemic antibiotics or isotretinoin (oral retinoid). During systemic acne tretman some cosmetic interventions (microneedling, laser) are postponed. After acne stabilization, components of Skin longevity (e.g. fractional laser) can be planned for scar management.
If a nevus not conforming to the ABCDE rule (asymmetry, irregular borders, color variation, diameter >6 mm, recent change), a newly appearing pigmented lesion or an ulcerated/non-healing lesion is identified during clinical examination, the patient is immediately referred for dermatology consultation and dermoscopy. This takes urgent priority — aesthetic interventions are postponed until the diagnosis is clear. Early detection saves lives.
Severe papulopustular or phymatous rosacea is managed under dermatology follow-up with topical ivermectin/metronidazole, oral doxycycline and, where indicated, isotretinoin. Energy-based components of Skin longevity (e.g. IPL for telangiectasias) are only planned in coordination with the specialist once the disease has been medically stabilized. Energy-based applications on an unstabilized rosacea can trigger a flare.
Patients with chronic plaque psoriasis involving the face require dermatology follow-up with topical vitamin D analogues, phototherapy, systemic agents (e.g. methotrexate) or biologics (e.g. anti-IL-17/23). The injection- and energy-based components of the Skin longevity protocol are not performed during active plaque periods due to risk of triggering (Köbner phenomenon). Once the disease is controlled, the plan is reviewed jointly with the specialist.
If there is dermatochalasis on the upper eyelid combined with ≥3 mm ptosis, or significant brow-tail descent with functional visual impairment, this is not a picture that can be corrected with non-invasive methods (botulinum toxin, fileri, energy-based tightening). The patient is referred for plastic-surgery consultation for blepharoplasty and/or surgical brow lift. After surgery, the Skin longevity protocol can be used in coordination with the surgeon for fine-tuning and maintenance.
When pronounced jowl descent on the jawline, prominent platysmal bands on the anterior neck and significant sub-mental fat excess are present together, this is an indication for surgical neck lift and, where required, platysmaplasty. This picture is not adequately corrected by energy-based tightening or threads, which give only limited, temporary results. A plastic-surgery consultation is openly recommended; after surgery, the Skin longevity protocol can be planned for skin-quality improvement and maintenance.
Lower-face skin laxity at Baker grade 3 or above — that is, marked skin redundancy, poor recoil when the skin is pulled, and deep nasolabial/marionette lines — exceeds the capacity of non-invasive methods. These patients are referred for plastic-surgery consultation for facelift options (SMAS lift, deep-plane lift variants). After 4–6 months of postoperative maintenance, components of Skin longevity can be planned in coordination with the surgeon.
In the presence of deep nasolabial and marionette folds together with visible deflation of midface fat compartments, advanced loss of zygomatic support and overall midface descent, an approach that simply fills with hyaluronic acid does not provide proportionate results and can produce over-volumization in the long term. For these patients, surgical fat grafting (lipofilling) combined with a midface lift is evaluated with a plastic surgeon. Skin longevity is used as a complementary protocol for skin health before and after surgery.
A brow midpoint drop of 4 mm or more, compensatory frontal hyperactivity with deepening horizontal forehead lines, and a "heavy brow" appearance after botulinum toxin together describe an anatomy in which toxin cannot lift the brow adequately. These patients are referred for plastic-surgery consultation for endoscopic or open surgical brow lift. Postoperatively, forehead and glabella dynamics are managed within the Skin longevity protocol using carefully titrated doses.
Disclaimer: This page is for general informational purposes and does not substitute for personal medical advice. Any tretman that may be appropriate for a given patient is individualized only after a detailed clinical examination and skin analysis; the criteria above should therefore not be read as a definitive "accept" or "reject" list. If you are unsure, or if you believe one of the "not suitable" categories above applies to you, please first consult your primary-care physician or the relevant specialist (dermatology, plastic surgery, psychiatry, etc.). Clinical decisions are always safer with an additional expert opinion; these referrals are not about closing the door but about finding the right timing and the right specialist for you.